Gemcitabine plus nab-paclitaxel versus gemcitabine alone in elderly patients aged 76 years or older with unresectable pancreatic cancer: A propensity score-matched multicenter prospective observational study.
Gemcitabine plus nab-paclitaxel versus gemcitabine alone in elderly patients aged 76 years or older with unresectable pancreatic cancer: A propensity score-matched multicenter prospective observational study.
复制标题
吉西他滨联合白蛋白结合型紫杉醇与单用吉西他滨治疗 76 岁或以上患有不可切除胰腺癌的老年患者：一项倾向评分匹配的多中心前瞻性观察研究。
DOI：
--
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Hiroshi
中科院分区：
文献类型：
--
作者：
1.Satoshi Kobayashi;Motoko Suzuki ,Makoto Ueno;Yuta Maruki ,Junji Furuse;Akiko Todaka;Masato Ozaka;Kunihiro Tsuji;Kazuhiko Shioji;Keitaro Doi;Yasushi Kojima;Hidetaka Tsumura;Kazunari Tanaka;Hajime Higuchi;Ken Kawabe;Takeharu Yamanaka;Hiroshi
